Fåhraeus Startup and Growth

Fåhraeus Startup and Growth is a venture capital fund established in 2021 and based in Lund, Sweden. The firm focuses on early-stage investments in life science and technology companies. By targeting emerging firms in these sectors, Fåhraeus aims to support innovation and growth, providing the necessary capital and expertise to help startups develop their ideas and bring products to market.

Emanuel Eriksson

Investor

10 past transactions

Aplagon

Venture Round in 2025
Aplagon is a biopharmaceutical company focused on the development of innovative antithrombotic compounds aimed at addressing unmet medical needs in patients experiencing complications from vascular interventions. The company specializes in creating biological mimetics of heparin proteoglycan, which are designed to effectively manage thrombotic occlusions and ischemic reperfusion injuries associated with vascular injuries. By prioritizing safety and efficacy, Aplagon seeks to deliver antithrombotic therapies that offer significant advantages over existing treatments, ultimately improving patient outcomes in challenging medical scenarios.

Speqta

Post in 2024
Speqta is a performance marketing company that owns and operates an advertising network as well as several digital products and services.

Yazen

Angel Round in 2022
Yazen is a digital healthcare platform specializing in personalized weight loss programs. It connects users with medical professionals, including doctors, dietitians, and personal trainers, to create tailored weight management plans combining lifestyle coaching and medical treatments.

Airsonett

Venture Round in 2022
Airsonett is a medical device company focused on developing non-pharmaceutical treatments for allergic asthma and eczema. Its flagship product, the Air4, employs patented Temperature-controlled Laminar Airflow (TLA) technology to create a cleaner breathing environment. This non-invasive home device effectively reduces allergens and airborne irritants in the patient's vicinity during rest and sleep, providing significant relief for individuals suffering from allergic asthma and atopic eczema. Operating primarily in Sweden and the UK, Airsonett aims to enhance the quality of life for patients by offering effective prophylactic treatments that minimize reliance on traditional asthma medications.

Melius Pharma

Venture Round in 2022
Melius Pharma is a pharmaceutical company dedicated to the development of innovative treatments for interstitial lung diseases, with a particular emphasis on addressing severe conditions that exhibit significant unmet clinical needs. The company specializes in creating solutions for chronic cough associated with idiopathic pulmonary fibrosis, aiming to enhance the quality of care for patients suffering from these challenging respiratory conditions. By focusing on these targeted therapies, Melius Pharma seeks to improve health outcomes and provide healthcare professionals with effective treatment options for managing chronic cough.

Nygen Analytics

Venture Round in 2022
Nygen Analytics specializes in providing cloud-based solutions for the analysis of single-cell genomic data. The company develops tools and services aimed at facilitating sustainable and cost-effective genomic data analysis. By focusing on user-centric applications, Nygen Analytics helps researchers overcome challenges in genomics research, streamlining processes and enhancing the accessibility of complex data. Their innovative platform is designed to support advancements in the field of genomics, making it easier for users to derive meaningful insights from their data.

Saveggy

Seed Round in 2022
Producer of edible, bio-based, and food-safe packaging intended to reduce food loss and waste along the supply chain through sustainable alternatives. The company's platform technology is fully scalable and is the only available edible alternative that complies with EU regulations for fruits and vegetables with edible peels, enabling clients to ensure more food reaches consumers around the world.

Moroxite F

Venture Round in 2022
Moroxite F is a company that specializes in developing innovative treatments for fractures, particularly in patients with osteoporosis. Its primary focus is on a regenerative medicine that utilizes a prolonged release system for hydroxyapatite binding drugs, specifically designed to enhance the anchoring of implants in fragile bones. By delivering hydroxyapatite particles directly at the interface of bone, the company aims to improve implant fixation, thereby reducing the incidence of fixation failures and the need for re-operations. This approach not only seeks to enhance the quality of life for osteoporotic patients but also aims to lower societal costs associated with fracture management.

Brick Technology

Seed Round in 2022
Brick is an app that solves the problem of electronics running out of battery. Download our app and find the nearest Brick station on the map, then rent a power bank (with cables) to charge your phone, tablet, headphones or whatever it is that is running out of battery. Return the power bank to any Brick station so that you can charge on the go. Stay in charge.

Oncorena

Venture Round in 2021
Oncorena is a pharmaceutical company focused on developing treatments for advanced kidney cancer. Its lead product, based on the naturally occurring toxin orellanine, selectively targets and eliminates renal cancer cells, aiming to provide a cure for patients with metastatic renal cancer.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.